11 Aug 2011
Half Yearly Report
August 11, 2011 – In order to meet its obligations under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Services Authority, Shire plc (“Shire” or the “Group”) (LSE: SHP, NASDAQ: SHPGY) is publishing today its Half Yearly Report for the six months ended June 30, 2011.
It should be noted that on July 28, 2011 Shire previously announced its results in respect of the same period.
For further information please contact:
Eric Rojas (firstname.lastname@example.org)
Sarah Elton-Farr (email@example.com)
+1 781 482 0999
+44 1256 894 157
Jessica Mann (firstname.lastname@example.org)
+44 1256 894 280
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (“ADHD”), human genetic therapies (“HGT”) and gastrointestinal (“GI”) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
To view the full half year report please click on the link below: